Vasculotide reduces pulmonary hyperpermeability in experimental pneumococcal
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Abstract
Background: Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide.
Despite effective antimicrobial therapy, CAP can induce pulmonary endothelial hyperpermeability resulting in
life-threatening lung failure due to an exaggerated host-pathogen interaction. Treatment of acute lung injury is
mainly supportive because key elements of inflammation-induced barrier disruption remain undetermined.
Angiopoietin-1 (Ang-1)-mediated Tie2 activation reduces, and the Ang-1 antagonist Ang-2 increases, inflammation
and endothelial permeability in sepsis. Vasculotide (VT) is a polyethylene glycol-clustered Tie2-binding peptide that
mimics the actions of Ang-1. The aim of our study was to experimentally test whether VT is capable of diminishing
pneumonia-induced lung injury.
Methods: VT binding and phosphorylation of Tie2 were analyzed using tryptophan fluorescence spectroscopy and
phospho-Tie-2 enzyme-linked immunosorbent assay. Human and murine lung endothelial cells were investigated
by immunofluorescence staining and electric cell-substrate impedance sensing. Pulmonary hyperpermeability was
quantified in VT-pretreated, isolated, perfused, and ventilated mouse lungs stimulated with the pneumococcal
exotoxin pneumolysin (PLY). Furthermore, Streptococcus pneumoniae-infected mice were therapeutically treated
with VT.
Results: VT showed dose-dependent binding and phosphorylation of Tie2. Pretreatment with VT protected lung
endothelial cell monolayers from PLY-induced disruption. In isolated mouse lungs, VT decreased PLY-induced
pulmonary permeability. Likewise, therapeutic treatment with VT of S. pneumoniae-infected mice significantly
reduced pneumonia-induced hyperpermeability. However, effects by VT on the pulmonary or systemic
inflammatory response were not observed.
Conclusions: VT promoted pulmonary endothelial stability and reduced lung permeability in different models of
pneumococcal pneumonia. Thus, VT may provide a novel therapeutic perspective for reduction of permeability in
pneumococcal pneumonia-induced lung injury.
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Background
Community-acquired pneumonia (CAP) is the most
common serious infectious disease worldwide [1–4].
Streptococcus pneumoniae is the most prevalent causal
pathogen identified in CAP [3, 5]. Reaching more than
10%, the lethality of hospitalized patients with pneumo-
nia is relatively high [6–8]. Despite effective antibiotic
therapy, pathogen-host interaction in pneumonia may
increase pulmonary endothelial permeability, leading to
the formation of interstitial and alveolar protein-rich
edema, and finally to life-threatening lung failure [9].
Mainly supportive therapies are available for acute lung
injury, but specific treatments to protect the pulmonary
barrier function are lacking [10–12]. Thus, there is a
need for novel therapeutic strategies in addition to anti-
biotics to avoid pneumonia-induced acute lung injury.
Angiopoietins (Ang-1 to Ang-4) are ligands for the re-
ceptor tyrosine kinase Tie2 [13]. Ang-1 and Ang-2, cur-
rently the best described angiopoietins, are well-known
contributors to angiogenesis [14] and regulators of in-
flammation and vascular leakage [15–18]. Constitutively
released Ang-1 activates the Tie2 receptor, resulting in
reduction of inflammation and apoptosis as well as
stabilization of endothelial barrier function [18–21]. In
contrast, Ang-2 supports inflammation and permeability
by acting as an Ang-1 antagonist at Tie2 [15, 22].
Vasculotide (VT) is a synthetic peptide clustered with
polyethylene glycol [23, 24]. VT was shown to protect
endothelial cells from lipopolysaccharide (LPS)-induced
disruption and to prevent endotoxemia-induced lung
vascular leakage [25], diminish barrier disruption in ex-
perimental sepsis [26] and acute kidney injury [27], and
increase the survival of mice with influenza pneumonia
[28]. However, its potential to support pulmonary barrier
function in severe pneumococcal pneumonia has not
been investigated so far.
In order to characterize effects of VT on pneumonia-
induced acute lung injury, we used several approaches
with differing levels of complexity. In vitro human and
murine pulmonary endothelial cell monolayers were pre-
treated with VT and stimulated with pneumolysin (PLY),
an exotoxin of S. pneumoniae [29, 30]. Likewise, ex vivo
perfused and ventilated mouse lungs were treated with VT
and stimulated with PLY. Finally, VT was applied in vivo
to treat mice with severe pneumococcal pneumonia
therapeutically. Some of the results presented here were
previously reported in the form of abstracts [31, 32].
Methods
Tryptophan fluorescence spectroscopy
Binding studies were carried out in 96 well plates
(Brand-plates pureGrade reference 781607; BRAND
GMBH +CO KG, Wertheim, Germany). Mouse Tie2Fc
receptor and human immunoglobulin G (IgG) Fc were
obtained from R&D Systems (Minneapolis, MN, USA).
Dilutions were prepared in HyClone™ Dulbecco’s PBS
(GE Healthcare Life Sciences, Mississauga, ON, Canada).
The saturation binding curve was prepared with all lig-
and dilutions and receptors as 2× concentrations. Equal
volumes of ligand and receptor were added to generate a
final 1× concentration (500 nM Tie2Fc final concentration).
Spectroscopic studies were performed on a SpectraMax
M2 fluorometer (Molecular Devices, Sunnyvale, CA, USA).
Measurements were taken at an excitation wavelength of
295 nm. Emission scans were set from 360 to 450 nm.
Tie2 phosphorylation analysis in vitro
C57BL/6 mouse primary lung microvascular endothelial
cells (Cell Biologics, Chicago, IL, USA) were grown in
endothelial cell medium with a kit (Cell Biologics) in
20% O2/5% CO2 in a 37 °C humidified chamber and split
1:2 once reaching 90–95% confluency. To examine the
activation of Tie2 by VT in mouse primary lung micro-
vascular endothelial cells, 95–100% confluent cells were
stimulated with VT (1, 10, 100, and 1000 ng/ml) in
serum-containing media for 15 minutes. Human Ang-1
(R&D Systems) was used as a positive control. VT was
synthesized, purified, and validated as described before
[24, 26, 33]. Cell lysates were collected using lysis buffer
recommended in the mouse phospho-Tie-2 enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems);
tyrosine-phosphorylated Tie2 and total Tie2 were
measured using ELISA kits (mouse phospho-Tie2 and
total-Tie2 ELISA kits; R&D Systems). Three to six inde-
pendent experiments were analyzed.
Immunofluorescence staining of human pulmonary
microvascular endothelial cells
Human pulmonary microvascular endothelial cells
(hPMVEC; PromoCell, Heidelberg, Germany), used at pas-
sages 4–6, were grown to confluence on glass slides, incu-
bated with VT (300 ng/ml) or sterile PBS as a control for
90 minutes and then stimulated with LPS (0.1 μg/ml) from
Escherichia coli (Sigma-Aldrich, Steinheim, Germany), PLY
(0.25, 0.5, 0.75 μg/ml) [34], or PBS. After 30 minutes, cells
were fixed in 3% formalin, and the tight junction protein
vascular endothelial (VE)-cadherin (1:400, goat antihuman
VE-cadherin; Santa Cruz Biotechnology, Santa Cruz, CA,
USA; secondary antibody 1:8000, Alexa Fluor 488 F(ab′)2
rabbit antigoat IgG (H+ L), Invitrogen, Darmstadt,
Germany) and actin fibers (1:2000; phalloidin Alexa
546-labeled; Invitrogen) were stained to evaluate cell
morphology [35]. 4′,6-diamidino-2-phenylindole stain-
ing (Sigma-Aldrich) was used to visualize cell nuclei.
The immunofluorescence of the cells was analyzed by
confocal microscopy using an LSM 780 microscope with
ZEN 2011 software (objective: Plan Apochromat × 63/1.40
oil; Carl Zeiss Microscopy, Jena, Germany).
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Animals
For all experiments, female C57BL/6 N mice (8 to
10 weeks old, weighing 18 to 20 g; Charles River
Laboratories, Sulzfeld, Germany) were used. Animals
were housed under specific pathogen-free conditions
under a 12–h/12-h light/dark cycle with free access to
food and water. Animal housing and experimental pro-
cedures complied with the Federation of European
Laboratory Animal Science Associations (FELASA)
guidelines and recommendations for the care and use of
laboratory animals.
Transcellular electrical resistance of murine lung
endothelial cells
Murine lung endothelial cells (mLEC) were isolated
and purified according to protocols published previously
[36, 37]. Briefly, mice were killed by an overdose of keta-
mine/xylazine. Lungs of four mice were pooled, minced,
and digested by dispase (20 ml, 5 U/ml; BD Biosciences,
Heidelberg, Germany) and DNase (20 ml, 0.5 mg/ml;
AppliChem GmbH, Darmstadt, Germany). The homogen-
ate was filtered, collected by centrifugation (300 × g), and
washed twice, and the resulting cell suspension was
incubated with antimouse VE-cadherin antibody (rat
antimouse CD 144; BD Pharmingen, San Diego, CA,
USA)-coated magnetic beads (sheep antirat IgG
DynaBeads; Invitrogen GmbH, Karlsruhe, Germany) for
positive isolation with the DynaMag-Spin magnet system
(Invitrogen). The isolated cells were resuspended in
Endothelial Cell Growth Medium MV2 (PromoCell),
seeded onto fibronectin-coated (Sigma-Aldrich) culture
dishes (diameter 35 mm), and grown to a confluent
monolayer in 3–4 days. Then, cells were split after
trypsinization [37], seeded and grown to confluence on
fibronectin-coated evaporated gold microelectrodes
(eight-well array with ten electrodes per well; ibidi GmbH,
Martinsried, Germany) connected to an electric cell-
substrate impedance sensing (ECIS) system (Applied
Biophysics, Troy, NY, USA) [38] for continuous monitoring
of transcellular electrical resistance (TER). Cells were pre-
treated withVT (2, 10, and 50 ng/ml) or PBS for 30 minutes
and then stimulated with PLY (0.75 μg/ml) or PBS for 3 h.
Isolated perfused mouse lung
Mouse lungs were prepared as described previously [39].
Briefly, anesthetized mice were tracheotomized and ven-
tilated. After sternotomy and cannulation of the left
atrium and pulmonary artery, lungs were perfused with
37 °C sterile Krebs-Henseleit hydroxyethyl-amylopectin
buffer (1 ml/minute) and ventilated by negative pressure
(Pexp −4.5, Pins −9.0 cmH2O) in a humidified chamber.
After a 20-minute steady state, continuous infusion of
VT (50 or 100 ng/ml) or PBS was commenced. Five mi-
nutes later, human serum albumin (HSA) was admixed
to the perfusate (0.04%) for permeability quantification.
Ten minutes thereafter, 1.4 μg/ml PLY was infused into
the pulmonary artery for 1 minute. Bronchoalveolar
lavage (BAL) was performed 30 minutes after PLY
application, and HSA concentration was measured in
bronchoalveolar fluid (BALF) [35, 40].
Murine pneumonia and vasculotide therapy
Mice were anesthetized with ketamine (80 mg/kg) and xyla-
zine (25 mg/kg) and transnasally inoculated with 5 × 106
colony-forming units (CFU) of S. pneumoniae (NCTC7978)
in 20 μl of sterile PBS as described before [35]. Sham-
infected control mice received 20 μl of sterile PBS. After
22 h, 34 h, and 46 h, body weight and rectal temperature
were measured, and different dosages of VT (100, 200, or
500 ng in 100 μl of PBS) or PBS were intravenously injected
into the tail vein. Twenty-four or forty-eight hours postin-
fection (p.i.), mice were anesthetized (160 mg/kg ketamine
and 75 mg/kg xylazine) and exsanguinated. The experimen-
tal design is shown in Additional file 1: Figure S1. Subse-
quently, lungs were flushed, and BAL was performed. To
determine permeability, HSA (1 mg/75 μl) was intraven-
ously infused 1 h before lung preparation, and the BALF/
plasma ratio was calculated as described elsewhere [35].
BALF leukocytes were differentiated by fluorescence-
activated cell sorting (FACSCanto II; BD Biosciences) using
forward- vs. side-scatter characteristics and peridinin
chlorophyll protein complex-CD45 (clone 30-F11; BD
Biosciences), V450-Ly6G (clone 1A8; BD Biosciences), and
phycoerythrin-F4/80 (clone BM8; eBioscience, Vienna,
Austria) staining. Blood leukocytes were quantified using a
scil Vet ABC Hematology Analyzer (scil animal care com-
pany GmbH, Viernheim, Germany). Cytokines from BALF
were measured with a multiplex assay (ProcartaPlex;
eBioscience), and plasma levels of interleukin (IL)-6 (BD
Biosciences) and KC (keratinocyte chemoattractant;
R&D Systems) were quantified by ELISA.
Identical experiments were performed separately for
histological analyses of the lungs. Mice were anesthetized
24 h or 48 h p.i. (160 mg/kg ketamine and 75 mg/kg xyla-
zine), heparinized, and exsanguinated. After ligation of the
trachea, mouse lungs were removed and immediately
immersion-fixed in 4% buffered formalin, embedded in
paraffin, cut into 2-μm-thick sections, and stained with
hematoxylin and eosin as described elsewhere [41, 42].
The degree of edema formation was assessed semi-
quantitatively (0 = no edema, 1 =minimal edema, 2 =mild
edema, 3 =moderate edema, 4 = severe edema). Three
evenly distributed sections per lung were microscopically
evaluated to assess edema formation.
Statistical analysis
Saturation binding data (Fig. 1a–c) are presented as
mean ± SEM and were calculated using normalized one-
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site specific binding and nonlinear regression. For the
Tie2 phosphorylation analysis (Fig. 1d), one-way analysis
of variance (with Dunnett’s post hoc multiple compari-
sons test) was used to compare treatment groups with
the vehicle-treated group. All other experimental data
are expressed as mean, mean + SEM, or mean ± SEM.
Groups were compared using the Mann-Whitney U test
followed by the Bonferroni-Holm correction, where indi-
cated. p Values < 0.05 were considered significant. Ana-
lyses were performed using Prism version 6.00 software
(GraphPad Software, La Jolla, CA, USA).
Results
Vasculotide binds and phosphorylates mouse Tie2
Using tryptophan fluorescence spectroscopy, a dose-
dependent increase in intrinsic fluorescence intensity
was observed with the incubation of recombinant mouse
Tie2Fc receptor and VT (Fig. 1a and b). The fluorescence
intensity was found to be saturable. The dissociation
constant of the normalized specific binding of VT to
mouse Tie2Fc was 34.95 nM (95% CI 2.92–66.97 nM). For
this calculation, the relative light units (RLU) were nor-
malized to the bottom plateau (RLU value of 0 nM VT)
and the top plateau at saturation. Significantly, no dose-
dependent increase in fluorescence intensity was observed
with recombinant human IgGFc and VT (Fig. 1c).
Furthermore, stimulation of mouse primary lung micro-
vascular endothelial cells with VT resulted in Tie2 phos-
phorylation in a dose-dependent manner (Fig. 1d).
Vasculotide reduced pneumolysin-evoked barrier
disruption of lung endothelial cells in vitro
In a first step, effects of VT on PLY-evoked barrier fail-
ure [35] in hPMVEC were analyzed. VT had been shown
to protect against LPS-induced cell damage [25]. For
comparability, we first stimulated cell monolayers with
LPS. In the absence of LPS or PLY, VE-cadherin staining
(Fig. 2a) revealed an intact monolayer with tight cell
a b
c d
Fig. 1 Vasculotide (VT) binds and phosphorylates mouse Tie2. a Fluorescence intensity with the incubation of mouse Tie2Fc receptor and VT
(closed circles) or VT alone (open squares). b Relative light units (RLU) of the specific binding of VT to Tie2Fc, which were corrected to the baseline
RLU values of VT alone, are shown. The dissociation constant of the normalized specific binding of VT to mouse Tie2Fc was 34.95 nM (95% CI
2.92–66.97 nM). Values were normalized to the bottom plateau (RLU value of 0 nM VT) and the top plateau at saturation. c No saturation of binding
is observed with human immunoglobulin G Fc and VT. d Mouse primary lung microvascular endothelial cells were stimulated with 1, 10, 100, and
1000 ng/ml VT and 800 ng/ml human angiopoietin-1 and normalized to the vehicle-treated group. Data represent mean ± SEM (n = 3–6). *p < 0.05,
**p < 0.01, ***p < 0.001 by one-way analysis of variance (Dunnett’s post hoc test)
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contacts and thin actin fibers, and no effect of VT pre-
treatment was observed As expected, PBS-pretreated
hPMVEC showed gap formation between cells and gen-
eration of stress fibers after LPS (0.1 μg/ml) or PLY
(0.25, 0.5 μg/ml) challenge, as well as strong cell
retraction and loss of cells after stimulation with
0.75 μg/ml PLY (Fig. 2a, upper row). Pretreatment with
VT (300 ng/ml) stabilized cell monolayers, protected
from gap formation, and reduced stress fibers as well as
cell loss (Fig. 2a, lower row).
In additional ECIS experiments, PLY stimulation
evoked a decrease in TER of mLEC monolayers,
displaying loss of endothelial integrity (Fig. 2b, solid
curve). Incubation of confluent mLEC monolayers with
VT attenuated the PLY-induced TER decrease in a dose-
dependent manner (Fig. 2b, dashed/dash-dotted curves).
Vasculotide reduced pneumolysin-evoked permeability in
isolated perfused and ventilated mouse lungs
PLY stimulation increased lung permeability 30 minutes
after application (Fig. 2c) as described before [35].
Treatment with VT 15 minutes before PLY application




Fig. 2 Vasculotide (VT) stabilized endothelial barrier function in vitro and ex vivo. a Confluent human pulmonary microvascular endothelial
cells (hPMVEC) were preincubated for 90 minutes with 300 ng/ml VT or solvent (PBS) and stimulated with lipopolysaccharide (LPS; 0.1 μg/ml),
pneumolysin (PLY; 0.25, 0.5, or 0.75 μg/ml), or PBS for 30 minutes. Cells were fixed and vascular endothelial (VE)-cadherin (green), actin fibers (red),
and cell nuclei (blue) were stained for immunofluorescence microscopy. Unstimulated, PBS-treated, or VT-treated cells showed intact monolayers
with tight intercellular contacts and thin actin fibers (red). In PBS-pretreated groups, the integrity between cell contacts was disrupted, and
hPMVEC showed gap formation (asterisks) and stress fibers (arrows) after LPS or PLY stimulation (upper row). Pretreatment with VT stabilized the
cell monolayer, avoided gap formation, and reduced stress fibers and cell loss from culture dishes (lower row). Representative images of three
independent experiments are shown for every group. a Bar = 20 μm (valid for all photomicrographs). b Transcellular electrical resistance (TER) of
isolated murine lung endothelial cell (mLEC) monolayers was continuously monitored. mLEC were pretreated for 30 minutes with VT (2, 10, or
50 ng/ml) or PBS and then stimulated with pneumolysin (PLY; 0.75 μg/ml). PLY stimulation decreased TER of mLEC monolayers, displaying loss of
endothelial integrity (solid curve). Preincubation with VT attenuated the PLY-induced TER decrease in a dose-dependent manner (dashed and
dash-dotted curves). c Ex vivo perfused and ventilated mouse lungs were pretreated with VT (50 ng/ml or 100 ng/ml) or PBS 15 minutes before
PLY stimulation (1.4 μg/ml). After 30 minutes, lung vascular permeability was assessed by quantifying the concentration of continuously infused
human serum albumin (HSA) in bronchoalveolar lavage fluid (BALF). Treatment with VT significantly decreased hyperpermeability of mouse
lungs as compared with PBS treatment. Values are given as mean (C; n = 4–7) or mean + SEM (D; n = 6–8). **p < 0.01, ***p < 0.001 between
indicated groups
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Vasculotide therapy protected pulmonary barrier function
without affecting immune response in murine
pneumococcal pneumonia
Mice infected with S. pneumoniae were treated with VT
when pneumonia was already established (starting point
22 h p.i.) [35, 43]. Body weight and temperature were
not affected by VT therapy compared with infected,
PBS-treated mice (Additional file 1: Figure S2A and B).
However, VT reduced lung hyperpermeability in a dose-
dependent fashion, with the highest dosage of VT
(500 ng) exerting a significant permeability reduction at
24 h and 48 h p.i. compared with PBS treatment (Fig 3a
and b). In a further set of experiments in which mice
were treated with the highest dosage of VT and with a
focus on the immune response after VT treatment, the
decreased pulmonary barrier disruption at 24 h and 48 h
after infection was confirmed (Fig. 4a and b). Histo-
logical analysis of lung tissue revealed reduced lung in-
jury of infected, VT-treated animals at 24 h and 48 h
after infection compared with infected, PBS-treated mice
(Additional file 1: Figure S3). Furthermore, infected,
PBS-treated mice showed massive perivascular edema
formation 24 h after infection, which was considerably
reduced by VT treatment (Fig. 4c and f). At 48 h p.i.,
the edematous perivascular spaces in the lungs were in-
creasingly infiltrated by neutrophils, without differences
between the VT-treated and untreated groups. However,
VT-treated mice showed less perivascular edema than
the untreated group (Fig. 4d and f). At 48 h p.i., a dis-
tinct alveolar edema formation was additionally ob-
served, which was diminished in VT-treated mice in
contrast to PBS-treated mice (Fig. 4e and g). Notably,
pulmonary leukocyte recruitment and pulmonary in-
flammatory cytokine release were not significantly af-
fected by VT treatment (Fig. 5a–d, Additional file 1:
Figure S4). Only IL-12p40 levels were reduced in BALF
48 h after infection (Fig. 5d). Furthermore, systemic in-
flammatory responses at 24 h and 48 h p.i. remained un-
affected by VT treatment, as indicated by quantification
of blood leukocytes (Fig. 6a and b) as well as IL-6 and
KC plasma levels (Fig. 6c and d). The latter were slightly
decreased by trend upon VT treatment, with only IL-6
levels at 24 h p.i. significantly reduced. Furthermore,
bacterial burden in BALF (Additional file 1: Figure S5A
and B) and blood (Additional file 1: Figure S5C and D)
was not significantly reduced by VT treatment in con-
trast to the PBS-treated groups at both time points. In
vitro testing failed to show a direct antimicrobial activity
of VT (Additional file 1: Figure S6).
Discussion
Despite potent antibiotic treatment, pathogen-host
interaction in severe pneumonia may evoke an increase
in pulmonary endothelial permeability [44], resulting in
life-threatening acute lung injury [45]. Virulence factors
of the pathogens, including specific bacterial toxins as
well as an uncontrolled host immune response, may
induce lung barrier dysfunction [2]. Therapeutic sta-
bilization of the pulmonary endothelial barrier is crucial
to reducing acute lung injury and lung edema in severe
pneumonia [11]. The present study provides evidence
that the novel Tie2 agonist VT promotes pulmonary
a b
Fig. 3 Vasculotide (VT) therapy decreased pulmonary hyperpermeability in Streptococcus pneumoniae-infected mice. S. pneumoniae-infected mice
(5 × 106 colony-forming units/mouse) were intravenously (i.v.) treated with VT (100, 200, or 500 ng) or PBS 22 h, 34 h, and 46 h postinfection (p.i.).
Lung preparation and bronchoalveolar lavage were performed 24 h or 48 h p.i. Human serum albumin (HSA) was i.v. administered 23 h or 47 h
p.i., and HSA bronchoalveolar lavage fluid (BALF)/plasma ratio was determined by enzyme-linked immunosorbent assay to quantify permeability.
At a dose of 500 ng, VT significantly reduced lung hyperpermeability 24 h (a) and 48 h (b) p.i. compared with the PBS-treated controls. Values are
given as mean + SEM (n = 5–7). *p < 0.05, **p < 0.01 between indicated groups
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Fig. 4 (See legend on next page.)
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barrier function in pneumococcal pneumonia-induced
lung injury. This synthetic peptide is chemically stable
[23–25] and was reported to improve endothelial barrier
function in different in vitro and in vivo experimental
models [25–28].
The present study shows, for the first time to our
knowledge, that VT directly binds to the murine Tie2 re-
ceptor with a dissociation constant in the low nanomolar
range. This observation correlates with the dose-
dependent phosphorylation of Tie2 following application
of VT to mouse lung microvascular endothelial cells.
The latter result confirms findings of other studies in
which researchers have investigated other cell types/tis-
sues [24–26, 28, 33].
In vitro we observed that VT protected hPMVEC from
PLY-induced damage. PLY is a hemolytic exotoxin and
an important virulence factor of S. pneumoniae [29, 30],
the most frequent pathogen in CAP [3, 5]. This protect-
ive effect of VT is in accordance with results reported by
David et al. [25], who showed that VT treatment pro-
tects hPMVEC after LPS stimulation.
To expand on these first results, we tested effects of VT
in mouse models of pneumonia of different complexity (in
vitro, ex vivo, and in vivo). Again, pretreatment with VT
protected from PLY-induced pulmonary hyperpermeabil-
ity in an in vitro model of isolated mLEC and in the more
complex ex vivo model of isolated perfused and ventilated
mouse lungs. These results are consistent with findings of
other groups showing a protective effect of VT in murine
endotoxemia and abdominal sepsis [25, 26], in acute skin
ionizing radiation in mice [33], and in experimental acute
kidney injury [27].
Next, we tested whether VT is capable of protecting from
pneumonia-induced lung injury in vivo. Using a murine
model of pneumococcal pneumonia, we chose a clinically
relevant therapeutic approach and treated mice intraven-
ously twice daily with VT, beginning when pneumonia had
already been established (22 h p.i.) [35, 43, 46]. In this ex-
perimental in vivo setting, VT was shown to quickly and
effectively reduce pulmonary hyperpermeability in a dose-
dependent manner. Two hours after the first VT applica-
tion, and likewise 48 h p.i. after threefold VT application,
the HSA BALF/plasma ratio was decreased. To test for
further effects of VT in pneumonia other than barrier
stabilization, we performed a second set of in vivo experi-
ments using VT at the highest dose (500 ng). We could re-
produce the significant protective effect of VT on
pneumonia-induced hyperpermeability and confirm these
findings with histological analyses of lungs. The distinct
perivascular edema formation was reduced in the VT-
treated group 24 h and 48 h p.i. Furthermore, lungs of
VT-treated mice were nearly devoid of the additional
massive alveolar edema formation observed in the infected
PBS-treated group 48 h p.i. This protection did not seem
to be caused by a decrease in the inflammatory response.
Pulmonary recruitment of immune cells, cytokine release,
and the systemic immune response at both investigated
time points (24 h and 48 h p.i.) was only slightly affected
by VT treatment. Furthermore, no significant effect of VT
on bacterial burden in lungs and blood was seen. These
results are consistent with the observation by Sugiyama et
al. [28], who showed a protective effect of VT on pulmon-
ary barrier function in a murine model of influenza pneu-
monia without affecting leukocyte influx into the lung or
repressing virus replication. However, the results differ
from the observations of Kümpers et al. [26], who showed
reductions in local and systemic inflammatory markers
after abdominal sepsis. A possible explanation for the seem-
ingly contradictory findings is the use of different treatment
protocols. In comparison to the work of Kümpers et al.,
who started the treatment at the beginning of peritoneal
sepsis (2 h after cecal ligation and puncture), we started at a
rather late time point when severe pneumonia was estab-
lished and exacerbated into acute lung injury and the re-
cruitment of leukocytes was already near the maximum. It
cannot be excluded that VT given in an earlier stage of the
disease might decrease pulmonary inflammation. Further
studies are necessary to investigate whether VT is generally
capable of influencing the pulmonary immune response in
pneumonia.
(See figure on previous page.)
Fig. 4 Improvement of lung barrier function by Vasculotide (VT) was associated with diminished edema formation. Streptococcus pneumoniae
(5 × 106 colony-forming units/mouse) or sham-infected mice were intravenously (i.v.) treated with VT (500 ng) or PBS 22 h, 34 h, and 46 h postinfection
(p.i.). Lungs were prepared, and bronchoalveolar lavage was performed 24 h or 48 h p.i. Human serum albumin (HSA) was i.v. administered 23 h or
47 h p.i., and HSA bronchoalveolar lavage fluid (BALF)/plasma ratio was determined by enzyme-linked immunosorbent assay to quantify permeability.
For histological analysis, lungs were prepared and fixed 24 h or 48 h p.i. a and b Lung permeability was decreased 24 h and 48 h p.i. upon VT
treatment. c Histological analysis revealed that infected and PBS-treated mice showed massive perivascular edema formation 24 h after infection
(asterisks), which was considerably reduced by VT treatment. d At 48 h p.i., the edematous perivascular spaces in the lungs were increasingly infiltrated
by neutrophils (asterisks), but without differences between the VT-treated and untreated infected groups. In the sham-infected groups, no edema
formation or other pathological changes could be seen in the perivascular spaces at both time points (arrows in c and d). e PBS-treated mice showed
massive alveolar edema formation 48 h after infection (asterisks), which was almost completely abolished (three of four mice) by VT treatment. f and
g Semiquantitative determination of perivascular (f) and alveolar (g) edema formation confirmed these observations. a and b Values are
given as mean + SEM (n = 8 for S. pneumoniae-infected groups or n = 5 for sham-infected groups). **p < 0.01 between indicated groups. c, d, and
e Representative images are shown (n = 3–4); n.p. not present. Bars = 100 μm (c, d), 50 μm (e). f and g Values are given as mean + SEM (n = 3–4)
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In our study, only the cytokine IL-12p40 was de-
creased in BALF 48 h after infection, and the proinflam-
matory cytokine IL-6 concentration in blood was
reduced after 24 h, whereas levels of all other analyzed
cytokines did not differ between groups. These results
could indicate an influence of VT on specific immune
response mechanisms. It cannot be excluded that VT
directly binds to the Tie2 receptor expressed on immune
cells as described for monocytes/macrophages in angio-
genesis [47–49] or in chronically asthmatic mice [50],
rather than affecting, for example, mechanisms of cell
recruitment into the lungs. However, most of our find-
ings suggest that VT primarily exerts a direct impact on
the pulmonary endothelial barrier. This assumption is
supported by our findings from studies of endothelial
cells and isolated perfused and ventilated lungs, which
both are devoid of recruited immune cells [51].
Conclusions
In summary, VT was shown to protect pulmonary bar-
rier function without relevantly diminishing the immune





Fig. 5 Vasculotide (VT) treatment was not associated with a reduced pulmonary immune response. Streptococcus pneumoniae (5 × 106 colony-forming
units/mouse) or sham-infected mice were intravenously (i.v.) treated with VT (500 ng) or PBS 22 h, 34 h, and 46 h postinfection (p.i.). Lungs were
prepared, and bronchoalveolar lavage was performed 24 h or 48 h p.i. Immune cells in bronchoalveolar lavage fluid (BALF) were differentiated by
fluorescence-activated cell sorting, and BALF cytokines were quantified. Pulmonary leukocyte recruitment (a, b) and BALF cytokine concentrations
(c, d) were not significantly reduced (except interleukin [IL]-12p40) by VT 24 h (a, c) and 48 h (b, d) after infection. Values are given as mean + SEM
(n = 8 for S. pneumoniae-infected groups or n = 5 for sham-infected groups). Dotted lines indicate lower detection limits, and dash-dotted
lines indicate upper detection limits, of the cytokine assay. *p < 0.05 between indicated groups. nd not detectable, PMN Polymorphonuclear cells,
S. pn. Streptococcus pneumoniae
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unaffected by VT treatment, thereby ensuring effective
bacterial elimination. Furthermore, an intact immune
system is also crucial to avoiding secondary infections.
The results of our study, together with characteristics of
VT, such as receptor specificity, chemical stability, and
low production costs [28], suggest that VT may possess
great potential as a novel therapeutic agent for reduc-
tion of permeability in pneumococcal pneumonia-
induced lung injury.
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